Evaluation of the Efficacy of Active Hexose Correlated Compound as an Adjuvant in Reducing Recurrence After Condyloma Cauterization
- PMID: 40282913
- PMCID: PMC12028437
- DOI: 10.3390/medicina61040622
Evaluation of the Efficacy of Active Hexose Correlated Compound as an Adjuvant in Reducing Recurrence After Condyloma Cauterization
Abstract
Background and Objectives: Human papillomavirus (HPV) is one of the most prevalent sexually transmitted illnesses. HPV is responsible for genital condyloma lesions. A durable and effective systemic treatment regimen has not been established for HPV-related infections. In the present study, our purpose was to evaluate the role of active hexose correlated compound (AHCC) in preventing relapse in patients who underwent cauterization for condyloma accuminata. Materials and Methods: A total of 244 individuals admitted to our hospital between January 2019 and June 2022 were diagnosed as having condyloma acuminata, and those who underwent condyloma cauterization were evaluated retrospectively. We included 133 individuals who met the criteria. Patients who received AHCC were scheduled for follow-up examinations at regular intervals every three months. Patients were divided into two groups and analyzed based on whether they did or did not use AHCC. Results: The average age of AHCC non-users was significantly greater than that of AHCC users (p < 0.01). The number of condylomas and the maximum condyloma diameter of AHCC users before treatment were found to be significantly higher than in AHCC non-users (p = 0.006 and p = 0.004, respectively). Among participants with recurrence, the number and diameter of condylomas in AHCC users were significantly lower than in AHCC non-users (p = 0.019 and p = 0.042, respectively). Conclusions: Although the usage of AHCC is not expected to help prevent recurrence after the cauterization of condylomata acuminate in all patients, physicians may consider AHCC as a nutritional supplement and supportive therapy in the absence of other systemic treatments. Consequently, the duration of AHCC support necessary to optimize the effect of AHCC use on relapse prevention requires further evaluation on the basis of both target IFN-β levels and HPV infection status.
Keywords: active hexose correlated compound; condylomata acuminate; human papillomavirus; relapse.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Effectiveness of physically ablative and pharmacological treatments for anal condyloma in HIV-infected men.PLoS One. 2018 Aug 1;13(8):e0199033. doi: 10.1371/journal.pone.0199033. eCollection 2018. PLoS One. 2018. PMID: 30067738 Free PMC article.
-
AHCC® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections.Front Oncol. 2022 Jun 22;12:881902. doi: 10.3389/fonc.2022.881902. eCollection 2022. Front Oncol. 2022. PMID: 35814366 Free PMC article.
-
ALA-PDT combined with cystoscopy: A method to eliminate refractory HPV infection in a patient with condyloma acuminata.Photodiagnosis Photodyn Ther. 2020 Sep;31:101763. doi: 10.1016/j.pdpdt.2020.101763. Epub 2020 Apr 7. Photodiagnosis Photodyn Ther. 2020. PMID: 32276115
-
Asian guidelines for condyloma acuminatum.J Infect Chemother. 2022 Jul;28(7):845-852. doi: 10.1016/j.jiac.2022.03.004. Epub 2022 Mar 25. J Infect Chemother. 2022. PMID: 35341674 Review.
-
Could the human papillomavirus vaccine prevent recurrence of ano-genital warts?: a systematic review and meta-analysis.Int J STD AIDS. 2020 Jun;31(7):606-612. doi: 10.1177/0956462420920142. Epub 2020 May 21. Int J STD AIDS. 2020. PMID: 32438856
References
-
- Furumoto H., Irahara M. Human papilloma virus (HPV) and cervical cancer. J. Med. Investig. 2002;49:124–133. - PubMed
-
- Gunter J. Genital and perianal warts: New treatment opportunities for human papillomavirus infection. Am. J. Obstet. Gynecol. 2003;189:S3–S11. - PubMed
-
- Thompson A.B., Flowers L.C. Sexually Transmitted Infections in Adolescence and Young Adulthood: A Practical Guide for Clinicians. Springer; Cham, Switzerland: 2020. Human papillomavirus (HPV) pp. 279–297.
-
- Chan P.K., Chang A.R., Yu M.Y., Li W.H., Chan M.Y., Yeung A.C., Cheung T.H., Yau T.N., Wong S.M., Yau C.W., et al. Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies. Int. J. Cancer. 2010;126:297–301. doi: 10.1002/ijc.24731. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous